(Q35056049)

6 August 2017

1 reference

title

Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents? (English)

1 reference

6 August 2017

1 reference

1 reference

Frank Narjes

1

1 reference

6 August 2017

Uwe Koch

series ordinal

2

1 reference

6 August 2017

Christian Steinkühler

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

153-163

1 reference

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

A second hepatitis C virus-encoded proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C virus replicons: potential role for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Determinants of substrate specificity in the NS3 serine proteinase of the hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Peptide-based inhibitors of the hepatitis C virus serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Novel approaches to the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C virus protease inhibitors: current progress and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Inhibiting viral proteases: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Hepatitis C therapeutics: current status and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Targeting HIV-1 protease: a test of drug-design methodologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Capped dipeptide alpha-ketoacid inhibitors of the HCV NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.153

10.1517/13543784.12.2.153

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference